蝮蛇抗栓酶治疗急性胰腺炎33例的疗效观察

急性胰腺炎的发病机制很多 ,有些发病机制尚未完全阐明 ,而“微循环障碍”在急性胰腺炎发病机制中的作用正日益受到关注 ,作者为探讨应用蝮蛇抗栓酶治疗急性胰腺炎的疗效 ,将 65例急性胰腺炎患者随机分为蛇毒组 33例和非蛇毒组 32例 ,均给予禁食 ,抑制胃酸和胰酶分泌 ,维持水和电解质平衡和应用抗生素等治疗 ,蛇毒组在此基础上加用蝮蛇抗栓酶 0 .5u加入 5%葡萄糖液 2 50 ml中静脉滴注 ,每天 1次 ,疗程 1 0天 ;非蛇毒组不加用其他药物。两组于入院时和治疗后 1个疗程后分别检测血液流变学、血淀粉酶、尿淀粉酶 ,并进行对照比较。结果 :1个疗…     

蝮蛇抗栓酶救治急性肺栓塞5例

我院应用蝮蛇抗栓酶救治急性肺动脉栓塞 5例 ,效果良好。现报告如下。1　资料与方法1 .1　病例情况　 5例均为急诊患者 ,均进行胸部拍片证实为肺动脉栓塞。男 2例 ,女 3例 ,年龄 39～ 72岁 ;合并冠心病 1例 ,肺心病 3例 ;病程 0 .5～ 3h。1 .2　给药方法　先做蝮蛇抗栓酶皮试阴性后应用。用药前查出凝血时间 ,正常者给予蝮蛇抗栓酶0 .5u加入 1 0 %葡萄糖注射液 2 50 ml中静滴 ,每日1次 ,1疗程为 2天至 1周 ,用药期间除治疗原发病用药外 ,未用其它药物。1 .3　观察项目　在用药前及用药 2天后分别观察 :胸痛程度 ,呼吸困难程度 ,肺部罗音 ,心…     

蝮蛇抗栓酶在内科临床上的新应用

蝮蛇抗栓酶 ( Svate)是从蝮蛇蛇毒中分离出的以精氨酸酶为主要成分的一种新型抗凝溶栓剂。具有抗凝、去纤、溶栓、降低血液粘稠度、改善微循环的作用[1] ,在我国应用于脑血栓形成、心肌梗死、冠脉溶栓、脉管炎等的临床治疗已近 2 0年历史。随着其药理学研究的进步 ,蝮蛇抗栓酶在内科临床应用不断扩展 ,对多种疾病展现了良好的治疗效果。现将近年来有关文献综述如下。1　临床应用1 .1　治疗肾病综合征　徐国良等 [2 ]用蝮蛇抗栓酶0 .5～ 0 .75u加入 5%葡萄糖 2 50 ml中静滴 ,每日 1次 ,1 4天为 1疗程 ,治疗 34例 ,总有效率 93.75% ,优于综合…     

精制蝮蛇抗栓酶治疗脑梗死322例

作者应用精制蝮蛇抗栓酶治疗脑梗死322例,疗效满意,现报告如下。1　临床资料1.1　一般资料　322例均为住院病人,其中男244例,女78例,年龄43～78岁,治疗前进行有关辅助检查,均确诊为脑梗死并且无禁忌症。1.2　疗效评定　按总后勤部卫生部编制的《临床疾病诊断依据治愈好转标准》评定,未达好转标准的为无效。1.3　治疗方法　用精制蝮蛇抗栓酶10u加5%葡萄糖液250ml静脉滴注,每天1次,15天为1疗程。1～2疗程后判断疗效,疗程间休息1周。2　结果　　治愈226例,占70.2%;好转78例,占24.2%;无效18例,占5.6%;总有效率94.4%。3　讨论　　脑梗死已成为中…     

蝮蛇抗栓酶配合高压氧治疗脑血栓形成的护理体会

我院从 1 989年开始应用蝮蛇抗栓酶配合高压氧治疗脑血栓形成患者 66例 ,效果满意 ,现将护理体会报告如下。1　临床资料　　本组 66例 ,男 36例 ,女 30例 ,年龄最大 76岁 ,最小 42岁 ,平均 58岁。病程最长 6年 ,最短4h。所有病例均用蝮蛇抗栓酶配合高压氧治疗。结果治愈 42例占 63.7% ,好转 2 1例 ,占 31 .8% ,效果不明显 3例 ,占 4.5%。2　护理体会2 .1　治疗操作中的护理问题　蝮蛇抗栓酶临床应用有效剂量 ,成人每天 0 .5～ 0 .75u加入 5%葡萄糖 2 50 ml中静滴 ,每天 1次 ,1 0～ 1 5天为 1疗程 ,一般 2～ 3个疗程后 ,即可收到满意疗效。应…     

蝮蛇抗栓酶治疗脑梗死256例

我科于 1 989年 7月至 1 995年 7月 ,用蝮蛇抗栓酶治疗脑梗死 2 56例 ,疗效满意 ,现报道如下。1　临床资料1 .1　一般资料　 2 56例均按 1 986年中华医学会第二届全国脑血管病学术会议第二次修订的标准进行诊断 ,均经头颅 CT确诊。其中 ,男 1 34例 ,女1 2 2例 ,年龄 39～ 70岁 ,平均 57岁 ,其中发病在3周内 1 86例 ,4周至半年 62例 ,半年以上 8例。1 .2　治疗方法　应用蝮蛇抗栓酶 (沈阳药学院生产 )治疗。经皮试阴性后 ,用蝮蛇抗栓酶 0 .5～0 .75u加入 5%葡萄糖液或生理盐水 2 50 ml中静滴 ,每日 1次 ,1 5天为 1疗程 ,一般用 1～ 2个疗程 …     

蝮蛇抗栓酶治疗腔隙性脑梗死血液流变学变化

我科用蝮蛇抗栓酶治疗 87例腔隙性脑梗死患者 ,疗效好。现将治疗前、后患者的血液流变学变化报告如下。1　资料与方法1 .1　一般资料　 87例患者均为我科住院病人 ,均符合第二次全国脑血管病学术会议制定的诊断标准 ,并经头颅 CT或 MRI证实 ,确诊为腔隙性脑梗死。其中男 59例 ,女 2 8例 ,年龄 42～ 83岁 ,平均 62 .5岁。1 .2　治疗方法　用蝮蛇抗栓酶 (沈阳药科大学生产 )做皮试 ,阴性者 ,将蝮蛇抗栓酶 0 .75u加入0 .9%生理盐水 2 0 0 ml中静脉滴注 ,每天 1次 ,1 5天为 1疗程。停药 3～ 5天 ,继续第 2疗程。治疗前后用 FL系列血液流变学…     

蝮蛇抗栓酶对老年Ⅱ型糖尿病患者血液流变学的影响

我院从1992年2月至1998年12月用蝮蛇抗栓酶治疗老年型糖尿病患者96例,取得良好疗效,现报告如下。1　临床资料1.1　病例选择　选住院的老年型糖尿病患者(按1985年WHO糖尿病研究组制订诊断标准确诊),同时合并高血脂、高粘血症96例,男49例,女47例,平均年龄(67±1.62)岁,糖尿病史5～20年,治疗前血糖为(9.2±1.02)mmol/L,尿糖～,尿酮体阳性19例。1.2　治疗方法　蝮蛇抗栓酶皮试阴性后,每日0.5u加0.9%氯化钠注射液250ml静脉滴注,疗程15天,治疗前、后分别查血糖、血脂、血粘度,结果经统计学处理,t检验,每周查外周血小板计数,出、凝血时间各1次。…     

蝮蛇抗栓酶治疗白塞氏病3例报告

本文报告了应用蝮蛇抗栓酶治疗３例白塞氏病的临床疗效,初步认为,优于其它药物。治疗方法是：蝮蛇抗栓酶３～４支加入２５０ｍｌ～５００ｍｌ液体中静点,每日１次,每２０天为一疗程,中间间隔３～７天,连用４～６个疗程。此后每半年巩固治疗２个疗程。蝮蛇抗栓酶治疗该病的可能机理是活血化瘀和免疫调节作用。     

蝮蛇抗栓酶伍用丹参川芎注射液治疗血栓96例疗效分析（摘要）

蝮蛇抗栓酶伍用丹参川芎注射液治疗血栓９６例疗效分析（摘要）十堰市第二人民医院罗会常,梁佑平本文报告：用蝮蛇抗栓酶０．５单位加入１０％葡萄糖静液脉滴注与丹参川芎注射液（每毫升含生药丹参１ｇ川芎０．１ｇ）１４──２０ｍｌ加入１０％葡萄糖液静脉滴注１４──...     

蝮蛇抗栓酶治疗庆大霉素中毒

应用蝮蛇抗栓酶治疗庆大霉素中毒6例,其中1例由于合并严重神经症状及应用蝮蛇抗栓酶时间延长,需8个月治愈,余5例因应用蝮蛇抗栓酶及时,两周即治愈.总之,应用蝮蛇抗栓酶治疗6例庆大霉素中毒患者均获得理想效果。     

Elevation of liver-galactosylhydroxylysyl glucosyltransferase activity in human primary hepatocellular carcinoma

The activity of L-GGT (EC 2.4.1.66), an enzyme catalyzing the intracellular biosynthesis of collagen, was determined in human primary hepatic cancer, acute viral hepatitis and cirrhotic liver tissues and compared to the mean level of enzyme activity in normal human liver tissues. The mean levels of L-GGT activity in primary hepatocellular carcinoma (PHC), acute viral hepatitis and cirrhotic tissues were 7.78, 2.69 and 2.16 times the mean level of enzyme activity in normal human liver tissues. The mean level of L-GGT activity in PHC was 3.61 times the mean level of L-GGT activity in cirrhosis and 2.90 times the mean value of liver enzyme activity in acute viral hepatitis. The findings in this study provide a basis for the highly elevated serum values of this intracellular enzyme in patients with primary hepatic cancer and the data indicate that L-GGT activity may be increased in primary liver cancer to compensate for an increased rate of collagen synthesis.     

Viral interference: A potential therapeutic method for chronic viral hepatitis?

Viral interference exists between different viral hepatitis. Acute Hepatitis C virus (HCV) super-infection on Hepatitis B virus (HBV) chronic carriers showed an inhibition of the HBV genome. And acute HBV super-infection on HCV chronic carriers indicated a similar interaction. In these cases, if the acute liver viral super-infection presents a self-limited course, the patients may be free from both viral infections or at least with undetectable underlying chronic viremia. The mechanism of viral interference is still undefined. Anyway this still leads to the hypothesis of using one hepatitis virus (live attenuated vaccine) to treat another hepatitis virus.     

DNA Polymerase in Virions of a Reptilian Type C Virus

A study was made of the DNA polymerase of reptilian type C virus isolated from Russell's viper spleen cells. Simultaneous detection experiments demonstrated the presence of 70S RNA and RNA-dependent DNA polymerase activity in reptilian type C virions. The endogenous activity was dependent on the addition of all four deoxynucleotide triphosphates and demonstrated an absolute requirement for a divalent cation. The reptilian viral DNA polymerase elutes from phosphocellulose at 0.22 M salt. In this respect, it is similar to the avian (avian myeloblastosis virus; AMV) viral enzyme but is different from the mammalian (Rauscher leukemia virus; RLV) viral enzyme which elutes at 0.4 M salt. The molecular weight of the viper DNA polymerase as estimated from glycerol gradient centrifugation is 109,000. It is a smaller enzyme than the AMV DNA polymerase (180,000 daltons) and somewhat larger than the RLV enzyme (70,000 daltons). A comparison of other properties of the type C reptilian DNA polymerase with the enzyme found in other type C oncogenic viruses is made.     

Investigation of association between plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G polymorphism frequency and plasma PAI-1 enzyme activity in patients with acute stroke

Aim: This study was carried out to determine if there is any association between plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G polymorphism and plasma PAI-1 enzyme activity in acute stroke patients. Methods: In this study, 333 genomic DNAs (from 253 acute stroke patients and 80 healthy subjects) were analyzed. Genomic DNAs were prepared from peripheral blood using a saline method. These DNAs were amplified by PCR method using primers specific for 4G and 5G alleles. PCR products were separated by 2% agarose gel electrophoresis and visualized by a charge coupled device (CCD) camera. PAI-1 enzyme activities were measured by ELISA method. The results were evaluated statistically with Student's t-test, chi(2)-test, one-way analysis of variance, and stepwise regression analysis. Results: In this study, frequency of PAI-1 gene 4G5G genotype was found to be low both in patients and controls. PAI-1 enzyme activities were significantly increased in acute stroke patients compared to controls. Although PAI-1 gene 4G5G genotype frequencies were low, the patients carrying this allele had highest plasma PAI-1 enzyme activity; likewise, although PAI-1 gene 4G4G genotype frequencies were high, the patients carrying this allele had lowest plasma PAI-1 enzyme activities. Homocysteine levels had a positive effect of 65% on plasma PAI-1 enzyme activities. Conclusion: Consequently, in this study, we may assert that PAI-1 gene, 4G4G and 5G5G genotypes, PAI-1 activity, and homocysteine level determination are significant criteria for identifying patients who are likely to develop stroke; on the other hand, a direct relation does not exist between gene polymorphism and enzyme activity.     

Neovir therapy in acute hepatitis C

Neovir, an inductor of interferon-alpha, was injected intramuscularly to 15 male patients aged 16-44 years with diagnosed acute viral hepatitis in a dose of 250 mg a day, 2-3 times a week, for 3 months. By the end of the therapy hepatitis C virus RNA could still be isolated in 84.6% of the patients; the values of AlaT, AsaT and alkaline phosphatase exceeded the normal levels twofold. The result of the therapy is regarded as ineffective.     

Metabolism of thyroxine in acute viral hepatitis

Aim of this report was to define the correlation between hepatic acute damage and thyroxine metabolism. We have studied plasma levels of T4, T3, rT3 and TSH in 18 adult male subjects with acute viral hepatitis. No significant variation of T4, T3 and TSH plasma levels was found in different phases of disease. However, plasma rT3 levels were clearly elevated in 72% of patients in the first 7 days (mean 440 pg/ml vs 198 pg/ml of normal controls) and in 17% of cases in the second 10 days of disease (mean 269 pg/ml). Plasma rT3 concentration was always normal in the subsequent phases of disease. Our results indicate a diversion of peripheral thyroxine metabolism in the early stages of acute hepatitis.     

清栓酶治疗冠心病人左心功能的评价

1988至1990年期间,我们采用SV、CO、SI、CI、HI、TPR六项心功能指标测定了清栓酶对45例冠心病治疗前后左心功能的变化,结合临床症状和心电图的观察,45例冠心病患者的心功能改善率为73.3％。因而提示我们清栓酶在纠正心肌缺血,改善左心功能,防治心力衰竭等方面具有较好的效果,为治疗冠心病提供了一个新的药物。     

Evaluation of serum guanase in hepatic diseases

Serum guanase activity was measured in 20 healthy adults and in 62 patients with acute viral hepatitis, chronic active hepatitis, chronic persistent hepatitis, liver cirrhosis and fatty liver. Guanase and gamma-GT in patients were elevated in 87 and 64%, respectively. Elevated guanase activities were found in most cases of acute viral hepatitis, as well as in chronic hepatopathies. In patients with acute viral hepatitis pathologic activities of guanase were found following partial or total normalization of other liver function tests.     

依达拉奉联合疏血通对急性脑梗死患者的临床疗效及机制研究

目的:探讨依达拉奉联合疏血通对急性脑梗死患者的临床疗效及其可能作用机制。方法:收集我院治疗的80例急性脑梗死患者,随机分为实验组和对照组,每组40例。对照组患者给予依达拉奉注射液30 mg+生理盐水100 mg静脉滴注,2次/d;实验组患者在对照组基础上给予疏血通注射液6 g+生理盐水250 m L静脉滴注,2次/d,14 d为1个疗程。治疗后,对两组患者的血清血清基质金属蛋白酶-9(MMP-9),血管内皮生长因子(VEGF)、NIHSS以及临床疗效进行检测并比较。结果:与治疗前相比,两组患者治疗后血清MMP-9、VEGF水平以及NIHSS评分均显著下降(P0.05);与对照组相比,实验组患者治疗后血清MMP-9、VEGF水平以及NIHSS评分均较低(P0.05),且治疗总有效率较高(P0.05)。结论:依达拉奉联合疏血通能够有效提高急性脑梗死患者的临床疗效,改善神经功能缺损,这可能与其降低患者血清基质金属蛋白酶-9(MMP-9)及血管内皮生长因子(VEGF)水平有关。